Myovant Sciences Ltd. Contracts & Agreements

Amended and Restated Manufacturing & Services Agreement by and between Excella GmbH & Co. KG and Myovant Sciences GmbH, dated April 2, 2021 (Filed With SEC on October 26, 2022)

Amendment No. 3 to Market Access Services Agreement by and between Sunovion Pharmaceuticals Inc. and Myovant Sciences GmbH, dated March 15, 2021 (Filed With SEC on October 26, 2022)

Amendment No. 4 to Market Access Services Agreement by and between Sunovion Pharmaceuticals Inc. and Myovant Sciences GmbH, dated August 9, 2022 (Filed With SEC on October 26, 2022)

Letter Agreement by and between Myovant Sciences GmbH and Pfizer, Inc. dated September 19, 2022 (Filed With SEC on October 26, 2022)

Agreement and Plan of Merger, dated as of October 23, 2022, among Myovant Sciences Ltd., Sumitovant Biopharma Ltd., Merger Sub and, solely with respect to Article IX and Annex A,... (Filed With SEC on October 24, 2022)

Voting and Support Agreement, dated as of October 23, 2022, between Myovant Sciences Ltd. and Sumitovant Biopharma Ltd (Filed With SEC on October 24, 2022)

Letter of Understanding between Myovant Sciences, Inc. and Matthew Lang (Filed With SEC on July 27, 2022)

Amendment No. 4 to License Agreement (Filed With SEC on May 11, 2022)

Non-Executive Director Compensation Policy (Filed With SEC on May 11, 2022)

Amendment No.1 to Myovant Sciences Ltd. 2020 Inducement Plan (Filed With SEC on March 25, 2022)

Employment Agreement, dated as of August 12, 2021, by and between Uneek Mehra and Myovant Sciences, Inc (Filed With SEC on October 26, 2021)

Separation Agreement and General Release, dated as of August 11, 2021, by and between Frank Karbe and Myovant Sciences, Inc (Filed With SEC on October 26, 2021)

Letter Agreement, dated July 27, 2021, by and between Myovant Sciences GmbH and Pfizer, Inc (Filed With SEC on October 26, 2021)

Letter Agreement (Filed With SEC on July 28, 2021)

Commercial Manufacturing & Supply Agreement, effective as of May 30, 2018, by and between Myovant Sciences GmbH and Takeda Pharmaceutical Company Limited (Filed With SEC on May 11, 2021)

Amendment No.2 to Market Access Services Agreement, dated as of January 25, 2021, by and between Sunovion Pharmaceuticals Inc. and Myovant Sciences GmbH (Filed With SEC on May 11, 2021)

Employment Agreement, dated as of January 4, 2021, by and between David Marek and Myovant Sciences, Inc (Filed With SEC on May 11, 2021)

Separation Agreement (Filed With SEC on May 11, 2021)

Employment Agreement, effective as of April 5, 2021, by and between Lauren Merendino and Myovant Sciences, Inc (Filed With SEC on May 11, 2021)

Form of Restricted Stock Unit Grant Notice and Award Agreement under 2016 Equity Incentive Plan, as amended (2019 Non-U.S. Form) (Filed With SEC on May 11, 2021)

Form of Restricted Stock Unit Grant Notice and Restricted Stock Unit Agreement under 2020 Inducement Plan (Non-U.S. Form) (Filed With SEC on May 11, 2021)

Form of 2021 Incentive Bonus Letter with Executive Officers (Filed With SEC on May 11, 2021)

Non-Employee Director Compensation Policy (Filed With SEC on May 11, 2021)

Amendment to Consulting Agreement, dated November 11, 2020, by and between the Registrant and Sumitovant BioPharma, Inc (Filed With SEC on February 11, 2021)

Amendment No. 3 to License Agreement, dated December 15, 2020, by and between the Registrant and Takeda Pharmaceuticals International AG (Filed With SEC on February 11, 2021)

Commitment Letter Amendment Letter, dated December 22, 2020, by and between Sumitomo Dainippon Pharma Co., Ltd. and the Registrant (Filed With SEC on February 11, 2021)

Amendment No.1 to Market Access Services Agreement, dated as of (Filed With SEC on February 11, 2021)

Market Access Services Agreement, dated as of August 1, 2020, by and between Sunovion Pharmaceuticals Inc. and Myovant Sciences GmbH (Filed With SEC on November 12, 2020)

Commercial Manufacturing and Supply Agreement, dated April 4, 2019, by and between Excella GmbH & Co. KG and Myovant Sciences GmbH (Filed With SEC on November 12, 2020)

Commitment Letter, dated August 5, 2020, by and between Sumitomo Dainippon Pharma Co., Ltd. and the Registrant (Filed With SEC on November 12, 2020)

Commitment Letter Amendment Letter (Filed With SEC on November 12, 2020)

2020 Inducement Plan (Filed With SEC on November 12, 2020)

Form of Option Grant Notice and Option Agreement under 2020 Inducement Plan (Filed With SEC on November 12, 2020)

Form of Restricted Stock Unit Grant Notice and (Filed With SEC on November 12, 2020)

Consulting Agreement, dated May 18, 2020, by and between the Registrant and Sumitovant BioPharma Ltd (Filed With SEC on August 11, 2020)

Description of Common Shares (Filed With SEC on May 18, 2020)

Letter Agreement, dated October 31, 2019, by and between the Registrant and Sumitomo Dainippon Pharma Co., Ltd (Filed With SEC on February 10, 2020)

Loan Agreement, dated as of December 27, 2019, by and among Sumitomo Dainippon Pharma Co., Ltd., as the Lender, the Registrant, as the Parent, and Myovant Sciences GmbH, as the... (Filed With SEC on February 10, 2020)

Investor Rights Agreement, dated as of December 27, 2019, by and among the Registrant, Sumitovant Biopharma Ltd. and Sumitomo Dainippon Pharma Co., Ltd (Filed With SEC on February 10, 2020)

Form of Amendment No.1 to the Stock Option Grant Notice and Option Agreement under 2016 Equity Incentive Plan, as amended (Filed With SEC on November 12, 2019)

Form of Restricted Stock Unit Grant Notice and Award Agreement under 2016 Equity Incentive Plan, as amended (2019 Form) (Filed With SEC on November 12, 2019)

Underwriting Agreement, by and between Myovant Sciences Ltd. and J.P. Morgan Securities LLC, Goldman Sachs & Co. LLC, Cowen and Company, LLC, and Evercore Group L.L.C., as... (Filed With SEC on May 31, 2019)

Amendment No.1 to Information Sharing and Cooperation Agreement, dated as of May 24, 2019, by and between Roivant Sciences Ltd. and the Registrant (Filed With SEC on May 24, 2019)

Restricted Stock Award Agreement, dated May 31, 2017, by and between Myovant Sciences Ltd. and Lynn Seely (Filed With SEC on May 24, 2019)

Form of Restricted Stock Unit Grant Notice and Award Agreement under 2016 Equity Incentive Plan, as amended (Filed With SEC on May 24, 2019)

Form of Restricted Stock Award Agreement under 2016 Equity Incentive Plan, as amended (Filed With SEC on May 24, 2019)

Non-Employee Director Compensation Policy (Filed With SEC on May 24, 2019)

Employment Agreement, dated as of November 1, 2018, by and between Kim Sablich and Myovant Sciences, Inc (Filed With SEC on February 7, 2019)

Amended and Restated Employment Agreement, dated as of November 7, 2018, by and between Lynn Seely, M.D. and Myovant Sciences, Inc (Filed With SEC on November 8, 2018)

Amended and Restated Employment Agreement, dated as of November 7, 2018, by and between Frank Karbe and Myovant Sciences, Inc (Filed With SEC on November 8, 2018)

Amended and Restated Employment Agreement, dated as of November 7, 2018, by and between Matt Lang and Myovant Sciences, Inc (Filed With SEC on November 8, 2018)

Amended and Restated Employment Agreement, dated as of November 7, 2018, by and between Juan Camilo Arjona Ferreira, M.D. and Myovant Sciences, Inc (Filed With SEC on November 8, 2018)

Waiver and Amendment to the Securities Purchase Agreement, dated as of March 28, 2018, by and among the Registrant, Myovant Holdings Limited, Myovant Sciences GmbH, Myovant... (Filed With SEC on August 7, 2018)

Second Waiver and Amendment to the Securities Purchase Agreement, dated as of March 30, 2018, , dated October 16, 2017, by and among the Registrant, Myovant Holdings Limited,... (Filed With SEC on August 7, 2018)

Commercial Manufacturing & Supply Agreement, effective as of May 30, 2018, by and between Myovant Sciences GmbH and Takeda Pharmaceutical Company Limited (Filed With SEC on August 7, 2018)

Underwriting Agreement, by and between Myovant Sciences Ltd. and J.P. Morgan Securities LLC, Goldman Sachs& Co. LLC and Barclays Capital Inc., as representatives of the... (Filed With SEC on July 13, 2018)

Independent Director Compensation Policy (Filed With SEC on June 7, 2018)

Sales Agreement, dated as of April 2, 2018, between Myovant Sciences Ltd. and Cowen and Company, LLC (Filed With SEC on April 3, 2018)

Warrant Agreement, dated March 26, 2018, issued to Hercules Capital, Inc (Filed With SEC on March 30, 2018)

Loan and Security Agreement, dated October 16, 2017, by and among the Registrant, Myovant Holdings Limited, Myovant Sciences GmbH, Myovant Sciences Ireland Limited, and Myovant... (Filed With SEC on February 13, 2018)

Securities Purchase Agreement, dated October 16, 2017, by and among the Registrant, Myovant Holdings Limited, Myovant Sciences GmbH, Myovant Sciences Ireland Limited, and Myovant... (Filed With SEC on February 13, 2018)

Equity Purchase Agreement, dated October 16, 2017, by and among the Registrant and NovaQuest Pharma Opportunities Fund IV, L.P. and NovaQuest Pharma Opportunities Fund IV... (Filed With SEC on February 13, 2018)

Employment Agreement, dated as of July 12, 2017, by and between Matthew Lang, JD and Myovant Sciences, Inc (Filed With SEC on November 13, 2017)

Employment Agreement, dated as of July 24, 2017, by and between Juan Camilo Arjona Ferreira, MD and Myovant Sciences, Inc (Filed With SEC on November 13, 2017)

Warrant Agreement, dated October 16, 2017, issued to Hercules Capital, Inc (Filed With SEC on October 16, 2017)

MYOVANT SCIENCES LTD. RESTRICTED STOCK UNIT GRANT NOTICE (2016 EQUITY INCENTIVE PLAN) (Filed With SEC on June 14, 2017)

MYOVANT SCIENCES, INC. EMPLOYMENT AGREEMENT (Filed With SEC on April 3, 2017)

AMENDED AND RESTATED SERVICES AGREEMENT (Filed With SEC on February 13, 2017)

SERVICES AGREEMENT (Filed With SEC on February 13, 2017)

LICENSEAGREEMENT by and between TAKEDA PHARMACEUTICALS INTERNATIONAL AG and ROIVANT ENDOCRINOLOGY LTD. Dated as of April 29, 2016 (Filed With SEC on October 25, 2016)

RIGHT OF FIRST NEGOTIATION AND BOARDOBSERVER AGREEMENT (Filed With SEC on October 24, 2016)

LICENSEAGREEMENT by and between TAKEDA PHARMACEUTICALS INTERNATIONAL AG and ROIVANT ENDOCRINOLOGY LTD. Dated as of April 29, 2016 (Filed With SEC on October 20, 2016)

AGREEMENT FOR THEMANUFACTURE & SUPPLY OF CLINICAL TRIAL MATERIAL BY AND BETWEEN TAKEDA PHARMACEUTICAL COMPANY LIMITED, AND MYOVANT SCIENCESLTD. DATE: JUNE 7, 2016 (Filed With SEC on October 20, 2016)

MYOVANT SCIENCES LTD. 2016 EQUITY INCENTIVE PLAN, AS AMENDED ANDRESTATED ADOPTED BY THE BOARD OFDIRECTORS: SEPTEMBER 26, 2016 APPROVED BY THESHAREHOLDERS: SEPTEMBER 29, 2016... (Filed With SEC on October 20, 2016)

Myovant Sciences Ltd. [] Shares 1 Common Shares ($0.00001 parvalue) Underwriting Agreement (Filed With SEC on October 17, 2016)

LICENSEAGREEMENT by and between TAKEDA PHARMACEUTICALS INTERNATIONAL AG and ROIVANT ENDOCRINOLOGY LTD. Dated as of April 29, 2016 (Filed With SEC on September 30, 2016)

AGREEMENT FOR THEMANUFACTURE & SUPPLY OF CLINICAL TRIAL MATERIAL BY AND BETWEEN TAKEDA PHARMACEUTICAL COMPANY LIMITED, AND MYOVANT SCIENCESLTD. DATE: JUNE 7, 2016 (Filed With SEC on September 30, 2016)

INVESTOR RIGHTS AGREEMENT (Filed With SEC on September 30, 2016)

ROIVANT ENDOCRINOLOGY LTD. WARRANT TO PURCHASE SHARES (Filed With SEC on September 30, 2016)

MYOVANT SCIENCES LTD. 2016 EQUITY INCENTIVE PLAN, AS AMENDED ANDRESTATED ADOPTED BY THE BOARD OFDIRECTORS: SEPTEMBER 26, 2016 APPROVED BY THESHAREHOLDERS: SEPTEMBER 29, 2016... (Filed With SEC on September 30, 2016)

MYOVANT SCIENCES LTD. STOCK OPTION GRANT NOTICE (2016 EQUITY INCENTIVE PLAN) (Filed With SEC on September 30, 2016)

MYOVANT SCIENCES LTD. EARLY EXERCISE STOCK PURCHASE AGREEMENT UNDER THE 2016 EQUITY INCENTIVE PLAN (Filed With SEC on September 30, 2016)

MYOVANT SCIENCES LTD. Indemnification Agreement (Filed With SEC on September 30, 2016)

SERVICESAGREEMENT (Filed With SEC on September 30, 2016)

OPTION AGREEMENT (Filed With SEC on September 30, 2016)

INFORMATIONSHARING AND COOPERATION AGREEMENT (Filed With SEC on September 30, 2016)

MYOVANT SCIENCES, INC. EMPLOYMENT AGREEMENT (Filed With SEC on September 30, 2016)

Myovant Sciences,Inc. 2000 Sierra Point Parkway, Suite 550, Brisbane, CA 94005 myovant.com (Filed With SEC on September 30, 2016)

Category

Industry

Companies

Contracts

Myovant Sciences Ltd. Contracts & Agreements